All Posts By

Smartkarma Daily Briefs

Aug 31
0

Daily Brief Consumer: Crocs Inc, Giant Network Group Co Ltd, Dongfeng Motor, Nexstar Broadcasting Group, Inc, Performance Food Group Co, Aptiv PLC, Tapestry Inc, Ford Motor Co, Madison Square Garden Sports Corp. and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?
  • Sticking With China; Bullish Outlook Intact. Buys in Consumer Discretionary, Materials, and Tech
  • Last Week In Event SPACE: Dongfeng Motor, Shibaura, HD Hyundai Heavy/HD Hyundai Mipo, Zijin Mining
  • Nexstar Media Group: Strategic M&A & Capital Allocation to Improve Its Competitive Positioning & Fuel Long-Term Growth!
  • Performance Food Group: Can Diversification Across Foodservice
  • Aptiv Is Splitting Up—And The Market’s About To Wake Up
  • Tapestry Inc.: Targeted Brand Investments & Product Innovation to Ensure Brand Remains Relevant & Competitive!
  • Ford’s 7 Million Recalls In 2025: A Red Flag Investors Can’t Ignore!
  • Madison Square Garden (MSG) Sports: Will NBA & NHL Media Deals Cement Its Financial Future?

Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?

By Baptista Research

  • Crocs, Inc. reported a solid performance in the second quarter despite facing ongoing market volatility.
  • The company achieved revenues of $1.1 billion, reflecting a 3% growth from the previous year.
  • Revenues for the Crocs brand alone rose by 4%, reaching $960 million, with a notable 16% growth in international markets.

Sticking With China; Bullish Outlook Intact. Buys in Consumer Discretionary, Materials, and Tech

By Joe Jasper

  • We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.
  • We will maintain our bullish intermediate-term view as long as market dynamics remain healthy and the SPX and ACWI-US are above 6028-6059 and $119-$121.
  • We remain overweight/continue to have a major focus on China (Shanghai Composite). It continues to offer the most attractive opportunities, with a significant number of today’s recommendations coming from China.

Last Week In Event SPACE: Dongfeng Motor, Shibaura, HD Hyundai Heavy/HD Hyundai Mipo, Zijin Mining

By David Blennerhassett

Nexstar Media Group: Strategic M&A & Capital Allocation to Improve Its Competitive Positioning & Fuel Long-Term Growth!

By Baptista Research

  • Nexstar Media Group’s second quarter of 2025 results revealed a mix of positive achievements and ongoing challenges, shaping a comprehensive investment thesis for the company.
  • The company’s net revenue stood at $1.23 billion, representing a decline of 3.2% compared to last year, largely due to decreased political advertising.
  • Despite this decline, Nexstar’s financial stability was upheld by adjusted EBITDA of $389 million and adjusted free cash flow of $101 million, reflecting effective expense management amidst a challenging advertising landscape.

Performance Food Group: Can Diversification Across Foodservice

By Baptista Research

  • Performance Food Group Company (PFG) has demonstrated strong financial performance in the fiscal year 2025, with promising indications for 2026.
  • The company reported net sales exceeding $63 billion, marking a significant year-over-year increase.
  • This growth was primarily driven by strategic market share gains in the food away-from-home industry and expansion of margins through improving business mix and operational efficiency.

Aptiv Is Splitting Up—And The Market’s About To Wake Up

By Baptista Research

  • Aptiv is no stranger to transformation.
  • Once pegged as a traditional auto-parts supplier, the company is now orchestrating a strategic pivot that could redefine how Wall Street values its business.
  • The upcoming spin-off of its Electrical Distribution Systems (EDS) unit, slated for early 2026, aims to carve out a clearer identity for the remaining core business: a high-growth platform deeply entrenched in advanced safety, automation, electrification, and digital edge computing.

Tapestry Inc.: Targeted Brand Investments & Product Innovation to Ensure Brand Remains Relevant & Competitive!

By Baptista Research

  • Tapestry has reported strong financial performance for fiscal year 2025, with revenue reaching an impressive $7 billion and an operating margin of 20%.
  • The company achieved these results despite a challenging macroeconomic environment, demonstrating the resilience and effectiveness of its strategies.
  • Tapestry has seen significant growth across key regions, particularly North America, China, and Europe, and has successfully attracted 6.8 million new customers in North America alone, with a substantial portion from the Gen Z and millennial demographics.

Ford’s 7 Million Recalls In 2025: A Red Flag Investors Can’t Ignore!

By Baptista Research

  • In a year that was supposed to be about electrification and forward momentum, Ford Motor Company finds itself grappling with a growing crisis: vehicle recalls.
  • As of late August 2025, the automaker has issued 105 separate recall notices, covering nearly 7 million vehicles—a record for the company and for the industry in recent memory.
  • The most recent recall involves 355,656 Fseries trucks from the 2025 and 2026 model years due to potential failures in the instrument panel display.

Madison Square Garden (MSG) Sports: Will NBA & NHL Media Deals Cement Its Financial Future?

By Baptista Research

  • Madison Square Garden Sports Corp. (MSG Sports) reported their fiscal 2025 results, highlighting both achievements and challenges that offer a nuanced perspective on the company’s current standing.
  • The company achieved more than $1 billion in revenues and an adjusted operating income of $38.2 million.
  • Despite this significant revenue figure, the financial year concluded with notable challenges in the fourth quarter, leading to an adjusted operating loss of $16.8 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Health Care: Cytokinetics Inc, Zylox-Tonbridge Medical Technology, Gemvax & Kael, Legend Biotech Corp, Mannkind Corp, Tempus AI and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?
  • China Healthcare Weekly (Aug.31) – P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results
  • Gemvax & Kael – Rights Offering of 249 Billion Won
  • Legend Biotech’s 136% Sales Surge Signals Explosive CARVYKTI Momentum; How Long Will It Last?
  • MannKind Buys scPharmaceuticals For $360 Million Bet: Can This Transform Its Future In Cardiorenal Care?
  • Tempus AI: An Insight Into Its Strong Genomics Portfolio, Market Position & Key Growth Drivers!

Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?

By Baptista Research

  • Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges.
  • The company’s focus remains on advancing its pipeline of muscle biology-focused therapies, particularly within cardiology.
  • A key development is the ongoing regulatory process for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).

China Healthcare Weekly (Aug.31) – P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results

By Xinyao (Criss) Wang

  • We strongly disagree with the valuation method of “P/R”. which is calculated by dividing market value by R&D expenses. It is still necessary to view the valuation system rationally.
  • Innovent surprisingly turned loss into profits for the first time in 25H1. Considering the future contribution of mazdutide and IBI363, valuation of Innovent may reach above RMB200 billion.
  • The logic of Zylox is import substitution. Based on strong fundamentals, if liquidity remains strong, reasonable P/E is 40-45x. Target share price is HK$25-29/share based on 2025 net profit.

Gemvax & Kael – Rights Offering of 249 Billion Won

By Douglas Kim

  • On 29 August, Gemvax & Kael (082270 KS) (Gemvax) announced a rights offering capital raise of 249 billion won.
  • Gemvax will issue 6.7 million new shares in this rights offering, representing 16% of its outstanding shares. 
  • The expected rights offering price is 37,100 won which is 13.4% lower than current price. We are negative on this rights offering. 

Legend Biotech’s 136% Sales Surge Signals Explosive CARVYKTI Momentum; How Long Will It Last?

By Baptista Research

  • Legend Biotech Corporation’s second quarter of 2025 was marked by significant milestones and notable financial and operational achievements, balanced by some ongoing challenges.
  • On the positive side, the company reported substantial growth in CARVYKTI sales, reaching $439 million, an increase of 136% year-over-year.
  • This robust growth underscores the rapid uptake of CARVYKTI, primarily driven by its expansion in second to fourthline settings for multiple myeloma treatments.

MannKind Buys scPharmaceuticals For $360 Million Bet: Can This Transform Its Future In Cardiorenal Care?

By Baptista Research

  • In reviewing MannKind Corporation’s latest financial performance and strategic initiatives, the company presents a nuanced investment outlook characterized by both opportunities and challenges.
  • MannKind reported a revenue increase of 6% year-over-year for the second quarter of 2025, with $77 million in total, and $155 million year-to-date, marking a 12% growth compared to the previous year.
  • This growth was primarily driven by Tyvaso DPI royalties, which rose by 22%, contributing $31 million in the second quarter.

Tempus AI: An Insight Into Its Strong Genomics Portfolio, Market Position & Key Growth Drivers!

By Baptista Research

  • Tempus AI’s second-quarter 2025 financial results showcased significant growth and evolution in its business segments, but also presented some challenges that investors might consider.
  • The company reported a revenue increase of 89.6% to $314.6 million, with a notable growth of 115% in Genomics revenue attributed to oncology and hereditary testing.
  • Data and Services revenue also rose by 35.7%, driven primarily by the company’s data licensing services.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Thematic (Sector/Industry): RCEP: Unlocking ASEAN’s Strategic Potential Amid the U.S.-China Trade Realignment and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • RCEP: Unlocking ASEAN’s Strategic Potential Amid the U.S.-China Trade Realignment
  • India’s Q1 FY 2026 GDP Surprise: 7.8% Growth Amid Tariff Turbulence
  • APAC Healthcare Weekly (Aug 31) – Terumo, Eisai, Chugai, Daiichi Sankyo, Beigene, Remegen, Telix

RCEP: Unlocking ASEAN’s Strategic Potential Amid the U.S.-China Trade Realignment

By Kim Peng Ang

  • ASEAN’s strategic growth, digital expansion, and supply chain diversification present unmatched investment opportunities amid global geopolitical shifts. Act now to capitalize on its transformative decade.  
  • As ASEAN strengthens regional trade and digital infrastructure, it offers resilient, high-margin opportunities for long-term investors seeking diversification and growth in a changing global landscape.  
  • ASEAN is reshaping the future of Asia’s economy—poised for rapid growth, innovation, and supply chain leadership. Seize this moment for strategic, long-term value creation.

India’s Q1 FY 2026 GDP Surprise: 7.8% Growth Amid Tariff Turbulence

By Nimish Maheshwari

  • India’s real GDP surged 7.8 % YoY in Q1 (April–June) of FY 2025‑26, well above expectations and the previous quarter’s 7.4 % pace.
  • The upswing, driven by robust services, agriculture, and government spending, underscores India’s macro resilience despite looming U.S. tariffs, offering a rare growth bright spot globally.
  • While Q1 numbers remain strong, the key question over the next 3–6 months is whether consumption, investments, and reforms can offset external shocks and sustain the momentum.

APAC Healthcare Weekly (Aug 31) – Terumo, Eisai, Chugai, Daiichi Sankyo, Beigene, Remegen, Telix

By Tina Banerjee

  • Terumo is acquiring OrganOx, a leading innovator in organ preservation devices. Eisai received FDA approval for once weekly Leqembi subcutaneous injection for maintenance dosing.
  • Chugai Pharmaceutical’s partner Eli Lilly announced positive topline results from the Phase 3 trial of oral GLP-1 drug candidate. Daiichi Sankyo received approval for Datroway in China.
  • Beigene announced positive topline results from a Phase 1/2 study of sonrotoclax in mantle cell lymphoma. Telix Pharmaceuticals received a Complete Response Letter from the FDA regarding Zircaix.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Event-Driven: (Mostly) Asia-Pac M&A: Santos and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • (Mostly) Asia-Pac M&A: Santos, Mayne Pharma, Shengjing Bank, Carenet, Austindo Nusantara, Ashimori
  • Last Week In Event SPACE: Dongfeng Motor, Shibaura, HD Hyundai Heavy/HD Hyundai Mipo, Zijin Mining
  • Weekly Deals Digest (31 Aug) – ENN Energy, Shengjing, Ashimori, Carenet, Shibaura, Mayne, Aux

(Mostly) Asia-Pac M&A: Santos, Mayne Pharma, Shengjing Bank, Carenet, Austindo Nusantara, Ashimori

By David Blennerhassett

Last Week In Event SPACE: Dongfeng Motor, Shibaura, HD Hyundai Heavy/HD Hyundai Mipo, Zijin Mining

By David Blennerhassett

Weekly Deals Digest (31 Aug) – ENN Energy, Shengjing, Ashimori, Carenet, Shibaura, Mayne, Aux

By Arun George

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Equity Bottom-Up: JFrog’s Artifactory Vision: Could It Become the World’s AI Model Registry? and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • JFrog’s Artifactory Vision: Could It Become the World’s AI Model Registry?
  • Exxon’s Secret Russia Talks Signal Energy Market Shock Tied To Trump-Putin Peace Gambit!
  • Deere & Company: Precision Agriculture Technology Integration & International Market Expansion Are Propelling Its Future Growth!
  • China Healthcare Weekly (Aug.31) – P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results
  • Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?
  • Stantec Inside the Data Center Boom: What 100+ Projects Reveal About Its Future!
  • Taiwan Dual-Listings Monitor: TSMC Premium Remains Elevated; ASE Drops Down to Near Parity
  • Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?
  • SoundHound: Initiation of Coverage- Why Are They Dominating QSR & Could Their 14
  • Coherent’s Data Center Breakthrough: The 1.6-Terabyte Revolution Is Here!

JFrog’s Artifactory Vision: Could It Become the World’s AI Model Registry?

By Baptista Research

  • JFrog reported their financial results for the second quarter of 2025, highlighting continued growth and strategic execution.
  • Total revenue for the quarter was $127.2 million, marking a 23% increase year-over-year, with cloud revenue growing by 45% to $57.1 million.
  • This growth highlights JFrog’s successful strategy of converting customers with usage above minimum commitments into annual contracts, reinforcing the predictability of revenue streams and strategic focus on cloud services.

Exxon’s Secret Russia Talks Signal Energy Market Shock Tied To Trump-Putin Peace Gambit!

By Baptista Research

  • In a stunning geopolitical development, ExxonMobil has reportedly engaged in secret discussions with Rosneft—Russia’s largest state-owned energy company—regarding a potential return to the Sakhalin-1 oil and gas project.
  • These talks, led by Exxon Senior Vice President Neil Chapman, signal a possible energy détente between Washington and Moscow, tied to broader negotiations aimed at ending the war in Ukraine.
  • The meetings were held under U.S. Treasury Department licenses that allow for discussions on stranded assets and involved back-channel diplomacy, including conversations between Exxon CEO Darren Woods and former President Donald Trump.

Deere & Company: Precision Agriculture Technology Integration & International Market Expansion Are Propelling Its Future Growth!

By Baptista Research

  • Deere & Company’s third-quarter earnings report presents a mixed outlook for the company, marked by ongoing challenges due to global uncertainties and shifting market dynamics, tempered with strategic operational efficiencies and modest positive trends in some segments.
  • The segments of Production and Precision Agriculture, Small Agriculture and Turf, and Construction and Forestry each tell a distinct story of both struggle and strategic positioning.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

China Healthcare Weekly (Aug.31) – P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results

By Xinyao (Criss) Wang

  • We strongly disagree with the valuation method of “P/R”. which is calculated by dividing market value by R&D expenses. It is still necessary to view the valuation system rationally.
  • Innovent surprisingly turned loss into profits for the first time in 25H1. Considering the future contribution of mazdutide and IBI363, valuation of Innovent may reach above RMB200 billion.
  • The logic of Zylox is import substitution. Based on strong fundamentals, if liquidity remains strong, reasonable P/E is 40-45x. Target share price is HK$25-29/share based on 2025 net profit.

Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?

By Baptista Research

  • Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges.
  • The company’s focus remains on advancing its pipeline of muscle biology-focused therapies, particularly within cardiology.
  • A key development is the ongoing regulatory process for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).

Stantec Inside the Data Center Boom: What 100+ Projects Reveal About Its Future!

By Baptista Research

  • Stantec’s second quarter of 2025 presents a mixed picture, with various factors suggesting both opportunities and challenges for potential investors.
  • The company reported net revenue of $1.6 billion, marking a 6.9% increase compared to the previous year.
  • This growth was primarily driven by a 4.8% in organic growth, pointing to consistent demand across its operations, particularly in sectors like water, transportation, mining, energy, and mission-critical projects.

Taiwan Dual-Listings Monitor: TSMC Premium Remains Elevated; ASE Drops Down to Near Parity

By Vincent Fernando, CFA

  • TSMC: +21.8% Premium; Wait for Higher Premium Before Fresh Short of the Spread
  • UMC: -0.6% Discount; Wait for More Extreme ADR Spread Level
  • ASE: +0.4% Premium; Good Level to Go Long the ADR Spread

Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?

By Baptista Research

  • Crocs, Inc. reported a solid performance in the second quarter despite facing ongoing market volatility.
  • The company achieved revenues of $1.1 billion, reflecting a 3% growth from the previous year.
  • Revenues for the Crocs brand alone rose by 4%, reaching $960 million, with a notable 16% growth in international markets.

SoundHound: Initiation of Coverage- Why Are They Dominating QSR & Could Their 14

By Baptista Research

  • SoundHound exhibited a noteworthy performance in the second quarter of 2025, recording its strongest ever quarterly revenue of $42.7 million, a significant surge of 217% compared to the previous year.
  • This growth was primarily driven by substantial advancements in their diverse business verticals: automotive, AI customer service for enterprises, and AI solutions for the restaurant industry.
  • The company highlighted its strategic acquisition initiatives, which have effectively enhanced growth trajectories and solidified its position as a key player in the conversational AI sector.

Coherent’s Data Center Breakthrough: The 1.6-Terabyte Revolution Is Here!

By Baptista Research

  • Coherent Inc.’s fourth quarter and full fiscal year 2025 results reflect both strong performance and some areas of challenges.
  • The company experienced a robust fiscal year with revenue hitting a record $5.81 billion, marking a 23% year-over-year increase.
  • This growth was propelled significantly by the company’s data center and communications business, with data center revenue alone increasing by 61% from the previous year.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Australia: Santos Ltd, Iron Ore, MMG Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • (Mostly) Asia-Pac M&A: Santos, Mayne Pharma, Shengjing Bank, Carenet, Austindo Nusantara, Ashimori
  • Iron Ore Giants Stay Bullish on India, China Demand Wobbles
  • MMG Reports Soaring Output From Peru Copper Mine

(Mostly) Asia-Pac M&A: Santos, Mayne Pharma, Shengjing Bank, Carenet, Austindo Nusantara, Ashimori

By David Blennerhassett

Iron Ore Giants Stay Bullish on India, China Demand Wobbles

By Umang Agrawal

  • Iron ore miners lift output guidance, signalling confidence despite China’s property slump and slowing steel demand.
  • India emerges as a critical growth driver yet cannot offset China’s structural steel demand weakness.
  • Rising supply from Simandou and peers heightens downside risk, keeping the iron ore outlook cautiously bearish.

MMG Reports Soaring Output From Peru Copper Mine

By Caixin Global

  • Chinese miner MMG Ltd. saw a dramatic surge in output at its Las Bambas copper mine in Peru in the first half of this year, helped by its efforts to improve its rocky relationship with locals.
  • In the six months through June, the mine produced about 210,000 tons of copper, up 67% year-on-year, with revenue from the project jumping 60% to $2 billion, according to the company’s latest earnings report.
  • Las Bambas accounted for nearly three-fourths of MMG’s total first-half revenue, which rose 47% to $2.8 billion.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief Macro: Iron Ore Giants Stay Bullish on India and more

By | Daily Briefs, Macro

In today’s briefing:

  • Iron Ore Giants Stay Bullish on India, China Demand Wobbles
  • Overview #33 Ignore the Noise, Follow the Money: China’s Next Leg Higher
  • 7 Main Reasons Driving Surging Ownership into MAG7 Stocks by Korean Investors: When Will They Sell?
  • CX Daily: Micro Drama Platforms Knock Down Paywalls as Viewers Lose Interest

Iron Ore Giants Stay Bullish on India, China Demand Wobbles

By Umang Agrawal

  • Iron ore miners lift output guidance, signalling confidence despite China’s property slump and slowing steel demand.
  • India emerges as a critical growth driver yet cannot offset China’s structural steel demand weakness.
  • Rising supply from Simandou and peers heightens downside risk, keeping the iron ore outlook cautiously bearish.

Overview #33 Ignore the Noise, Follow the Money: China’s Next Leg Higher

By Rikki Malik

  • A review of recent events/data impacting our investment themes and outlook
  • Chinese onshore markets now on a roll- will it continue?
  • The fight over critical materials heats up as the rally broadens out

7 Main Reasons Driving Surging Ownership into MAG7 Stocks by Korean Investors: When Will They Sell?

By Douglas Kim

  • In this insight, we discuss the sharp capital flight out of Korea into major stocks in the US in the past several years, especially into the MAG7 stocks.
  • We provide seven major reasons why Koreans’ investments in the US stocks (especially MAG7) have been surging in the past several years. 
  • When will they sell? We provide some clues on this.

CX Daily: Micro Drama Platforms Knock Down Paywalls as Viewers Lose Interest

By Caixin Global

  • Videos /In Depth: Micro drama platforms knock down paywalls as viewers lose interest
  • Energy /: China’s wind and solar power capacity has more than tripled since 2020
  • Education /: Top Chinese students forgo elite universities for vocational schools

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief South Korea: Gemvax & Kael and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Gemvax & Kael – Rights Offering of 249 Billion Won

Gemvax & Kael – Rights Offering of 249 Billion Won

By Douglas Kim

  • On 29 August, Gemvax & Kael (082270 KS) (Gemvax) announced a rights offering capital raise of 249 billion won.
  • Gemvax will issue 6.7 million new shares in this rights offering, representing 16% of its outstanding shares. 
  • The expected rights offering price is 37,100 won which is 13.4% lower than current price. We are negative on this rights offering. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief United States: JFrog, Exxon Mobil, Deere & Co, Cytokinetics Inc, Crocs Inc, SoundHound AI , Aptiv PLC, Coherent Inc, DLocal, Avery Dennison and more

By | Daily Briefs, United States

In today’s briefing:

  • JFrog’s Artifactory Vision: Could It Become the World’s AI Model Registry?
  • Exxon’s Secret Russia Talks Signal Energy Market Shock Tied To Trump-Putin Peace Gambit!
  • Deere & Company: Precision Agriculture Technology Integration & International Market Expansion Are Propelling Its Future Growth!
  • Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?
  • Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?
  • SoundHound: Initiation of Coverage- Why Are They Dominating QSR & Could Their 14
  • Aptiv Is Splitting Up—And The Market’s About To Wake Up
  • Coherent’s Data Center Breakthrough: The 1.6-Terabyte Revolution Is Here!
  • DLocal Bets Big on Stablecoins: A Hidden Payments Power Play?
  • Avery Dennison’s $390 Million Flooring Adhesives Bet: Can It Stick?

JFrog’s Artifactory Vision: Could It Become the World’s AI Model Registry?

By Baptista Research

  • JFrog reported their financial results for the second quarter of 2025, highlighting continued growth and strategic execution.
  • Total revenue for the quarter was $127.2 million, marking a 23% increase year-over-year, with cloud revenue growing by 45% to $57.1 million.
  • This growth highlights JFrog’s successful strategy of converting customers with usage above minimum commitments into annual contracts, reinforcing the predictability of revenue streams and strategic focus on cloud services.

Exxon’s Secret Russia Talks Signal Energy Market Shock Tied To Trump-Putin Peace Gambit!

By Baptista Research

  • In a stunning geopolitical development, ExxonMobil has reportedly engaged in secret discussions with Rosneft—Russia’s largest state-owned energy company—regarding a potential return to the Sakhalin-1 oil and gas project.
  • These talks, led by Exxon Senior Vice President Neil Chapman, signal a possible energy détente between Washington and Moscow, tied to broader negotiations aimed at ending the war in Ukraine.
  • The meetings were held under U.S. Treasury Department licenses that allow for discussions on stranded assets and involved back-channel diplomacy, including conversations between Exxon CEO Darren Woods and former President Donald Trump.

Deere & Company: Precision Agriculture Technology Integration & International Market Expansion Are Propelling Its Future Growth!

By Baptista Research

  • Deere & Company’s third-quarter earnings report presents a mixed outlook for the company, marked by ongoing challenges due to global uncertainties and shifting market dynamics, tempered with strategic operational efficiencies and modest positive trends in some segments.
  • The segments of Production and Precision Agriculture, Small Agriculture and Turf, and Construction and Forestry each tell a distinct story of both struggle and strategic positioning.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?

By Baptista Research

  • Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges.
  • The company’s focus remains on advancing its pipeline of muscle biology-focused therapies, particularly within cardiology.
  • A key development is the ongoing regulatory process for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).

Crocs Inc: How Are They Being Impacted By Consumer Dynamics & The Latest Market Trends?

By Baptista Research

  • Crocs, Inc. reported a solid performance in the second quarter despite facing ongoing market volatility.
  • The company achieved revenues of $1.1 billion, reflecting a 3% growth from the previous year.
  • Revenues for the Crocs brand alone rose by 4%, reaching $960 million, with a notable 16% growth in international markets.

SoundHound: Initiation of Coverage- Why Are They Dominating QSR & Could Their 14

By Baptista Research

  • SoundHound exhibited a noteworthy performance in the second quarter of 2025, recording its strongest ever quarterly revenue of $42.7 million, a significant surge of 217% compared to the previous year.
  • This growth was primarily driven by substantial advancements in their diverse business verticals: automotive, AI customer service for enterprises, and AI solutions for the restaurant industry.
  • The company highlighted its strategic acquisition initiatives, which have effectively enhanced growth trajectories and solidified its position as a key player in the conversational AI sector.

Aptiv Is Splitting Up—And The Market’s About To Wake Up

By Baptista Research

  • Aptiv is no stranger to transformation.
  • Once pegged as a traditional auto-parts supplier, the company is now orchestrating a strategic pivot that could redefine how Wall Street values its business.
  • The upcoming spin-off of its Electrical Distribution Systems (EDS) unit, slated for early 2026, aims to carve out a clearer identity for the remaining core business: a high-growth platform deeply entrenched in advanced safety, automation, electrification, and digital edge computing.

Coherent’s Data Center Breakthrough: The 1.6-Terabyte Revolution Is Here!

By Baptista Research

  • Coherent Inc.’s fourth quarter and full fiscal year 2025 results reflect both strong performance and some areas of challenges.
  • The company experienced a robust fiscal year with revenue hitting a record $5.81 billion, marking a 23% year-over-year increase.
  • This growth was propelled significantly by the company’s data center and communications business, with data center revenue alone increasing by 61% from the previous year.

DLocal Bets Big on Stablecoins: A Hidden Payments Power Play?

By Baptista Research

  • dLocal Limited’s latest earnings report for Q2 2025 highlights a period of strong financial performance, business expansion, and strategic enhancements, although it is tempered by certain macroeconomic risks and strategic decisions impacting the bottom line.
  • On the positive side, the company posted record results across its key financial metrics.
  • Total Payment Volume (TPV) reached an all-time high of $9.2 billion, marking a 53% year-over-year increase.

Avery Dennison’s $390 Million Flooring Adhesives Bet: Can It Stick?

By Baptista Research

  • Avery Dennison Corporation, a global materials science and manufacturing company, reported its second quarter results ending June 28, 2025.
  • The company delivered adjusted earnings per share (EPS) of $2.42, aligning with the previous year’s results.
  • This performance was achieved amid a challenging macroeconomic environment, characterized by trade policy changes impacting its operations, especially within the apparel and retail sectors.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Aug 31
0

Daily Brief India: InterGlobe Aviation Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • Quiddity Leaderboard BSE ​​​​SENSEX Dec25: Tech Mahindra Likely to Escape Sensex Deletion

Quiddity Leaderboard BSE ​​​​SENSEX Dec25: Tech Mahindra Likely to Escape Sensex Deletion

By Janaghan Jeyakumar, CFA

  • BSE SENSEX represents the 30 largest stocks listed in the Bombay Stock Exchange (BSE) of India.
  • In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX Index in the December 2025 index rebal event.
  • As things stand, there will be no index changes for the BSE SENSEX index.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free